Subtopic Deep Dive
BRAF Mutations Colorectal Cancer
Research Guide
What is BRAF Mutations Colorectal Cancer?
BRAF mutations in colorectal cancer refer to oncogenic alterations, primarily V600E, in the BRAF gene that drive aggressive tumor biology and resistance to EGFR inhibitors in a subset of metastatic cases.
BRAF V600E occurs in 8-12% of colorectal cancers, associating with poor prognosis and right-sided tumors (Di Nicolantonio et al., 2008; 1584 citations). These mutations predict lack of response to cetuximab or panitumumab unless combined with BRAF/MEK inhibitors (Kopetz et al., 2019; 1383 citations). Over 20 papers in the corpus detail prevalence, combinations like encorafenib/binimetinib/cetuximab, and immunotherapy rationale.
Why It Matters
BRAF-mutant CRC shows median survival under 12 months with standard therapy, but encorafenib, binimetinib, and cetuximab triple therapy extends OS to 15.4 months versus 9.9 months (Kopetz et al., 2019). This regimen is now NCCN-recommended for first-line metastatic BRAF V600E cases (Benson et al., 2017). Immunotherapy combinations address MSI-H overlap in 15-20% of cases, improving outcomes where chemo fails (Ganesh et al., 2019; Sargent et al., 2010). Targeted strategies reduce ineffective treatments, guiding precision oncology in 10% of mCRC patients.
Key Research Challenges
EGFR Inhibitor Resistance
BRAF V600E mutations block cetuximab/panitumumab response even in KRAS wild-type patients (Di Nicolantonio et al., 2008; Amado et al., 2008). Feedback activation of EGFR limits single-agent BRAF inhibition. Triple combinations overcome this but require biomarker testing.
Aggressive Tumor Biology
BRAF-mutant CRC links to peritoneal metastasis and poor OS (Marisa et al., 2013). Molecular subtypes show distinct gene expression profiles worsening prognosis. Integrating Immunoscore refines risk stratification (Galon et al., 2013).
Optimal Combination Sequencing
Encorafenib/binimetinib/cetuximab improves response rates to 26% but secondary resistance emerges (Kopetz et al., 2019). MSI-H subsets may benefit from immunotherapy first (Ganesh et al., 2019). Trials needed for adjuvant settings (Xie et al., 2020).
Essential Papers
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G. Amado, Michael Wolf, Marc Peeters et al. · 2008 · Journal of Clinical Oncology · 3.1K citations
Purpose Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating m...
Immunotherapy in colorectal cancer: rationale, challenges and potential
Karuna Ganesh, Zsofia K. Stadler, Andrea Cercek et al. · 2019 · Nature Reviews Gastroenterology & Hepatology · 1.9K citations
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang · 2020 · Signal Transduction and Targeted Therapy · 1.6K citations
Abstract Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have...
Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · 2008 · Journal of Clinical Oncology · 1.6K citations
Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not respons...
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent, Silvia Marsoni, Geneviève Monges et al. · 2010 · Journal of Clinical Oncology · 1.6K citations
Purpose Prior reports have indicated that patients with colon cancer who demonstrate high-level microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have improved survival and...
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Inés Mármol, Cristina Sánchez‐de‐Diego, Alberto Pradilla-Dieste et al. · 2017 · International Journal of Molecular Sciences · 1.5K citations
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence increasing ...
Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Laëtitia Marisa, Aurélien de Reyniès, Alex Duval et al. · 2013 · PLoS Medicine · 1.5K citations
We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA marke...
Reading Guide
Foundational Papers
Read Di Nicolantonio et al. (2008) first for BRAF as EGFR resistance marker (1584 citations), then Amado et al. (2008) for KRAS context (3139 citations), and Sargent et al. (2010) for MSI-H interactions (1582 citations).
Recent Advances
Study Kopetz et al. (2019) for encorafenib/binimetinib/cetuximab phase 3 results (1383 citations), Ganesh et al. (2019) for immunotherapy rationale (1906 citations), and Xie et al. (2020) for targeted therapy review (1589 citations).
Core Methods
BRAF V600E testing via PCR/sequencing; treatments include BRAF/MEK/EGFR inhibitors. Molecular subtyping (Marisa et al., 2013) and Immunoscore (Galon et al., 2013) aid stratification.
How PapersFlow Helps You Research BRAF Mutations Colorectal Cancer
Discover & Search
Research Agent uses searchPapers('BRAF V600E colorectal cancer encorafenib') to retrieve Kopetz et al. (2019), then citationGraph reveals 500+ downstream studies on combinations. findSimilarPapers on Di Nicolantonio et al. (2008) surfaces resistance mechanisms. exaSearch queries 'BRAF mutant CRC immunotherapy overlap' for Ganesh et al. (2019).
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Kopetz et al. (2019), then runPythonAnalysis with pandas computes HR from Kaplan-Meier curves (e.g., HR=0.60, p<0.001). verifyResponse(CoVe) cross-checks mutation prevalence claims against Sargent et al. (2010). GRADE grading scores encorafenib evidence as high-quality randomized data.
Synthesize & Write
Synthesis Agent detects gaps like post-progression therapies via contradiction flagging across Xie et al. (2020) and Kopetz et al. (2019). Writing Agent uses latexEditText for BRAF pathway revisions, latexSyncCitations integrates 10 papers, and latexCompile generates review sections. exportMermaid visualizes EGFR-BRAF-MEK feedback loops.
Use Cases
"Extract survival statistics from BRAF inhibitor trials in CRC and plot HR confidence intervals"
Research Agent → searchPapers('encorafenib BRAF CRC') → Analysis Agent → readPaperContent(Kopetz 2019) → runPythonAnalysis(pandas HR plot, matplotlib CI visualization) → researcher gets PNG hazard ratio graph with 95% CIs.
"Draft LaTeX section on BRAF V600E therapy recommendations with citations"
Synthesis Agent → gap detection('BRAF CRC guidelines') → Writing Agent → latexEditText('NCCN recs') → latexSyncCitations(Benson 2017, Kopetz 2019) → latexCompile → researcher gets PDF section with synchronized refs and table.
"Find code for analyzing BRAF mutation frequencies in TCGA CRC datasets"
Research Agent → searchPapers('BRAF TCGA CRC') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets R script for V600E prevalence computation from 600+ samples.
Automated Workflows
Deep Research workflow scans 50+ BRAF CRC papers, chains searchPapers → citationGraph → GRADE summary, outputting structured report with mutation rates and therapy ORRs. DeepScan applies 7-step CoVe to verify 'immunotherapy in BRAF/MSI-H CRC' from Ganesh et al. (2019), flagging overlaps. Theorizer generates hypotheses on BRAF-Immunoscore integration from Galon et al. (2013) and Kopetz et al. (2019).
Frequently Asked Questions
What defines BRAF mutations in colorectal cancer?
BRAF V600E is the dominant mutation in 8-12% of CRC, activating MAPK pathway and causing EGFR inhibitor resistance (Di Nicolantonio et al., 2008).
What are key methods for treating BRAF-mutant CRC?
Triple therapy with encorafenib, binimetinib, and cetuximab yields 26% ORR and OS 15.4 months (Kopetz et al., 2019). MSI-H cases use immunotherapy (Ganesh et al., 2019).
What are landmark papers on BRAF in CRC?
Di Nicolantonio et al. (2008; 1584 citations) proved BRAF predicts anti-EGFR failure. Kopetz et al. (2019; 1383 citations) validated triple therapy in phase 3 BEACON trial.
What open problems remain in BRAF-mutant CRC?
Secondary resistance mechanisms post-triple therapy and adjuvant trial data are unresolved (Xie et al., 2020). Optimal sequencing with immunotherapy needs RCTs.
Research Colorectal Cancer Treatments and Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching BRAF Mutations Colorectal Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers